KKR and Impilo Acquire Immedica Pharma

IK Partners Acquires Medica Group

July 7, 2023

Healthcare Services

IK Partners, via newly incorporated Moonlight Bidco Limited, has completed its acquisition of Medica Group Plc, a market-leading teleradiology and imaging-services provider headquartered in Hastings, UK. The transaction (effective 6 July 2023) takes Medica private; IK says it will support Medica's growth by investing in people, technology and new capabilities, including through M&A.

Merck to Acquire Imago BioSciences, Inc.

November 21, 2022

Pharmaceuticals

Merck has agreed to acquire clinical-stage biopharmaceutical company Imago BioSciences for $36.00 per share, representing an approximate equity value of $1.35 billion. The acquisition adds Imago's lead LSD1 inhibitor bomedemstat to Merck's hematology pipeline and is expected to close after a tender offer and customary regulatory clearances in early 2023.

Orkla Health Acquires NutraQ from Impilo

June 15, 2021

E-Commerce

On 15 June 2021 Orkla Health completed the acquisition of NutraQ from Nordic private equity owner Impilo. NutraQ is a Norway-founded, subscription-based D2C health and wellness platform that expanded across the Nordics under Impilo and delivered strong revenue and earnings growth. Orkla said the deal will help accelerate NutraQ's geographic expansion and growth across new product categories.

iuvo BioScience Acquires Promedica International

January 18, 2024

Healthcare Services

iuvo BioScience, a Rochester-based specialty preclinical and clinical services provider backed by Ampersand Capital Partners, has acquired Promedica International, an ophthalmology-focused clinical CRO headquartered in Costa Mesa, California. The deal combines iuvo's laboratory and consulting capabilities with Promedica's ophthalmic clinical trial expertise to create an integrated end-to-end ophthalmology clinical research offering.

PharmaLogic Holdings Corp. Acquires Majority Stake in Agilera Pharma AS

April 10, 2025

Pharmaceuticals

PharmaLogic Holdings Corp. has agreed to acquire a majority stake in Norway-based Agilera Pharma AS from the Institute for Energy Technology (IFE), creating an expanded, integrated global CDMO focused on radiopharmaceutical therapeutics. The deal strengthens PharmaLogic's manufacturing, development, and distribution capabilities for radiopharmaceuticals and is expected to close in June 2025, pending customary approvals.

Evotec SE Makes Strategic Equity Investment in IMIDomics, Inc.

February 15, 2022

Biotechnology

Evotec SE has made a minority equity investment in IMIDomics, Inc., and will take a board seat as part of the transaction; financial terms were not disclosed. The investment is intended to advance IMIDomics' Precision Discovery Engine and strengthen collaboration between Evotec and IMIDomics on data-driven drug discovery for immune-mediated inflammatory diseases.